How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
MRI Contrast Agents Market
- By Product Type: Gadolinium-based Contrast Agents (GBCAs), Iron Oxide Nanoparticles, Manganese-based Contrast Agents, Blood Pool Contrast Agents, Others
- By Application: Neurological Imaging, Cardiovascular Imaging, Oncological Imaging, Musculoskeletal Imaging, Abdominal Imaging
- By End User: Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Research Institutes
- By Molecular Structure: Linear Gadolinium Agents, Macrocyclic Gadolinium Agents, Superparamagnetic Iron Oxide Nanoparticles (SPIONs)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Gadolinium-based Contrast Agents (GBCAs) leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the MRI Contrast Agents Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 4
Molecular Structure 3
Companies profiled
Bayer AG
Bracco Imaging S.p.A.
GE Healthcare
Guerbet Group
Mallinckrodt Pharmaceuticals
Lantheus Medical Imaging
Siemens Healthineers
Philips Healthcare
Fujifilm Holdings Corporation
Canon Medical Systems Corporation
Sino Biopharmaceutical Limited
Sumitomo Dainippon Pharma Co. Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bracco Imaging S.p.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →GE Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Guerbet Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mallinckrodt Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Lantheus Medical Imaging
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Fujifilm Holdings Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Canon Medical Systems Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sino Biopharmaceutical Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sumitomo Dainippon Pharma Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Eisai Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →BioPal Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Advanced Magnetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,649M by 2033 · 10.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Gadolinium-based Contrast Agents (GBCAs)60.7
- Iron Oxide Nanoparticles11.6
- Manganese-based Contrast Agents8.0
- Blood Pool Contrast Agents8.8
- Others10.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,395M → $3,390M · 11.7%
Europe$972.0M → $2,457M · 12.3%
Asia Pacific$887.4M → $1,915M · 10.1%
Latin America$549.4M → $1,154M · 9.7%
Middle East and Africa$422.6M → $1,045M · 12.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.832026
10.842027
10.852028
10.862029
10.882030
10.882031
10.902032
10.912033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bayer AG17.4
- Bracco Imaging S.p.A.14.8
- GE Healthcare12.1
- Guerbet Group12.2
- Mallinckrodt Pharmaceuticals8.7
- Lantheus Medical Imaging6.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type23.1%
Application25.6%
End User31.2%
Molecular Structure20.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe24.7
- Asia Pacific19.2
- Latin America11.6
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bayer AG | 84 | 87 | 94 | 89 | 94 | 73 | 87 |
| Bracco Imaging S.p.A. | 76 | 79 | 89 | 93 | 87 | 73 | 83 |
| GE Healthcare | 88 | 72 | 74 | 80 | 81 | 84 | 80 |
| Guerbet Group | 69 | 65 | 66 | 65 | 72 | 67 | 67 |
| Mallinckrodt Pharmaceuticals | 64 | 54 | 56 | 66 | 70 | 70 | 63 |
| Lantheus Medical Imaging | 55 | 64 | 65 | 56 | 65 | 68 | 62 |
| Siemens Healthineers | 61 | 64 | 51 | 49 | 52 | 52 | 55 |
| Philips Healthcare | 38 | 49 | 47 | 56 | 49 | 35 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bayer AG
- Bracco Imaging S.p.A.
- GE Healthcare
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bayer AG | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bracco Imaging S.p.A. | ✓ | ✓ | ◐ | ✓ | ◐ | − |
| GE Healthcare | ◐ | − | ✓ | ◐ | ✓ | ◐ |
| Guerbet Group | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| Mallinckrodt Pharmaceuticals | ◐ | − | ◐ | ✓ | ◐ | ◐ |
| Lantheus Medical Imaging | − | ◐ | − | − | ✓ | ✓ |
| Siemens Healthineers | ◐ | ◐ | ◐ | − | − | ◐ |
| Philips Healthcare | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Bayer AG87
2Bracco Imaging S.p.A.83
3GE Healthcare80
4Guerbet Group67
5Mallinckrodt Pharmaceuticals63
6Lantheus Medical Imaging62
7Siemens Healthineers55
8Philips Healthcare46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Bayer AGBracco Imaging S.p.A.GE Healthcare
Challenger1
Strong scale, closing on the leaders.
Guerbet Group
Contender2
Focused players with pockets of strength.
Mallinckrodt PharmaceuticalsLantheus Medical Imaging
Niche2
Specialists in a single segment or region.
Siemens HealthineersPhilips Healthcare
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across MRI Contrast Agents Market — a $335M beachhead inside a $5.76B market.
Beachhead (SOM)$335Mobtainable near-term
Serviceable (SAM)$2.04Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Gadolinium-based Contrast Agents (GBCAs)
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Iron Oxide Nanoparticles
Strong fit — clear ROI and a fast path to value.
End user66 fit
Manganese-based Contrast Agents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel29%
Digital / self-serve17%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win MRI Contrast Agents Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified26%
Evaluation12%
Closed-won6%
$18.9KCAC
$66KLTV
3.5:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
MRI Contrast Agents Market is a durable-growth opportunity — $9.90B by 2033, compounding at 9.6%.
TAM · 2025$4.75Btoday
TAM · 2033$9.90Bforecast
CAGR9.6%2027–2033
Cumulative$63.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.90BTotal addressable market
SAM$3.56BServiceable available market
SOM$685MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.6% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.90BLarge & growingTAM by 2033 at 9.6% CAGR
$3.56BServiceable nowreachable with today’s model
$685MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.72BBear6.2% CAGR
$9.90BBase9.6% CAGR
$12.7BBull12.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
MRI Contrast Agents Market — a $7.26B market by 2033. Plan: grow share from 6.7% to 12.8%.
Market size · 2033$7.26Btotal addressable
Market CAGR10.4%2027–2033
Target share12.8%from 6.7% today
Revenue ambition$930Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 12.8% | At risk |
| Revenue | $507M | $930M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 34.9% | 42.9% | At risk |
| Customer retention | 88.7% | 92.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $127M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the MRI Contrast Agents Market conversation — a $4.71B market you can size, segment and defend in minutes.
Market size · 2033$4.71Btotal opportunity
Growth5.0%CAGR to 2033
Addressable buyers1,253+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 4 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Bayer AGBracco Imaging S.p.A.GE HealthcareGuerbet GroupMallinckrodt PharmaceuticalsLantheus Medical ImagingSiemens HealthineersPhilips Healthcare+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your MRI Contrast Agents Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
MRI Contrast Agents Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Inclusion Body Myositis Market
Market size, share, segmentation and regional forecast.
$569M market · 2025 base year
View reportHormone Replacement Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportMeningioma Drug Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportHemoglobinopathy Drugs Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportHemoglobinopathy Testing Services Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportHemoglobinopathy Treatment Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportHemagglutinin 5 Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportManidipine Hydrochloride Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportHelminthic Infestations Therapeutics Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportHard Gelatin Capsules Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportLiquid Embolics Market
Market size, share, segmentation and regional forecast.
$810M market · 2025 base year
View reportGrass Pollen Allergy Drug Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.